| Prev Close: | 28.70 |
|---|---|
| Open: | 28.71 |
| Bid: | 28.77 x 1600 |
| Ask: | 28.82 x 2500 |
| 1y Target Est: | 31.47 |
| Beta: | 0.81 |
| Next Earnings Date: | 29-Jul-13 |
| Day's Range: | 28.31 - 28.83 |
|---|---|
| 52wk Range: | 21.40 - 31.15 |
| Volume: | 43,973,795 |
| Avg Vol (3m): | 32,369,000 |
| Market Cap: | 204.14B |
| P/E (ttm): | 13.78 |
| EPS (ttm): | 2.09 |
| Div & Yield: | 0.96 (3.30%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Stocks Climb on Dovish Fed Comments; Bernanke Up Nextat CNBC(Tue 4:07PM EDT)
- Correction: Pfizer-Study Halted storyAP(Tue 3:52PM EDT)
- Dow Today: Pfizer (PFE) Higher Dow Today: Pfizer (PFE) Lowerat TheStreet(Tue 2:39PM EDT)
- The Top 3 Diseases Caused by Stressat Motley Fool(Tue 2:28PM EDT)
- Midday Glance: Pharmaceuticals companiesAP(Tue 1:16PM EDT)
- After A Big Rally, Pfizer Might Need Some Restat Investopedia(Tue 11:45AM EDT)
- SAC's Martoma says U.S. impedes defense in fraud caseReuters(Tue 11:20AM EDT)
- JPMorgan Could Maintian Joint Chair/CEO Role, Molycorp Boosted On Favorable Report and 3 More Hot Stocksat Wall St. Cheat Sheet(Tue 11:07AM EDT)
- Early Glance: Pharmaceuticals companiesAP(Tue 10:36AM EDT)
- Johnson & Johnson Stock Checkup for Mayat Motley Fool(Tue 2:06AM EDT)
- Pfizer halts study of non-Hodgkin's lymphoma drugAP(Mon, May 20)
- ‘Love Hormone’ Promises Safer Births After Pfizer Flopat Bloomberg(Mon, May 20)
- Final Glance: Pharmaceuticals companiesAP(Mon, May 20)
- Pfizer halts study of lymphoma drug unlikely to help survivalat Reuters(Mon, May 20)
- Can Pfizer’s Love Hormone Cut Down Maternal Mortality?at Wall St. Cheat Sheet(Mon, May 20)
Press Releases
- Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to FutilityBusiness Wire(Mon, May 20)
- Pfizer Announces 11 Abstracts for Tofacitinib to Be Presented at the European League Against Rheumatism (EULAR) 2013 Annual MeetingBusiness Wire(Mon, May 13)
- Pain Therapeutics Files Form 8-K Regarding Correspondence From Pfizer, Inc.GlobeNewswire(Fri, May 10)
Reports
- PFE: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 21)
- Thomson Reuters Stock Report - PFIZER INC. (PFE-N)Thomson Reuters Stock Report(May 21)
- Trading Report for (PFE). A detailed report, including free correlated market...Stock Traders Daily(May 21)